bluebirdbio.com (BLUE) - Net Profit

Official company branding of bluebird bio (BLUE)

bluebird bio, Inc. (BLUE) generates revenue through the sale of high-cost genetic therapies and timely insurance reimbursements. The company's profit demonstrates current financial stability, where -0.20 reflects the latest metric value. Growth potential is constrained by fierce competition for clinic access and risks associated with international patent protection and the complexities of importing bioccomponents.

Net Profit: bluebird bio, Inc (BLUE) for 07/04/2022 - 06/07/2025

Analytical breakdowns and data insights for company bluebird bio (BLUE)

- share price and consensus valuation forecast:
Price Chart bluebird bio, Inc|BLUE - Consensus Target
- market capitalization indicators:
Market Capitalization bluebird bio, Inc|BLUE - Enterprise Value
- book capitalization data:
Net Asset Value per Share bluebird bio|BLUE - Book Capitalization|Market Value to Book Value Ratio bluebirdbio.com|BLUE - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient bluebird bio, Inc.|BLUE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital bluebird bio Inc.|BLUE - Company Aggregate Debts|Debt to Book Value Ratio bluebird bio, Inc|BLUE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings bluebird bio|Quick Liquidity bluebirdbio.com
- company profitability and valuation multiples indicators:
BLUE - Net Profit
Fundamental valuation:bluebird bio, Inc
Mass-produced product of bluebird bio Inc.

Investors often waver between current yield and the risk of capital loss while attempting to find a point of objective truth. The bottom line of bluebird bio, Inc. (BLUE) reflects daily net income as an impartial indicator of fundamental efficiency, where financial results depend directly on the precision of ultra-cold biomaterial logistics, which are critical for maintaining cell viability in the treatment of rare diseases.

Key competitors

TEM (Tempus AI) - Company Net Income|Net Income QGEN|Net Profit ionispharma.com|Net Profit RGEN|RNA - Company Net Income|Net Profit CRSP (CRISPR Therapeutics Corp)|GeneDx Corp - Company Net Income|Ultragenyx Pharmaceutical - Net Profit|Net Financial Result beamtx.com BEAM|Sarepta (SRPT) - Company Net Income|Twist Bioscience Inc - Final Profit|TXG (10x Genomics Corp) - Net Profit|Company Profit NTLA (Intellia Corp)|Net Income STOK (Stoke Therapeutics)|BLFS (biolifesolutions.com) - Final Profit|Net Profit WVE (Wave Life Sciences Ltd.)|Maze Therapeutics, Inc. - Company Net Income|Sionna Pharma - Net Profit|Net Financial Result Prime Medicine Bio PRME|Taysha Gene Therapies (TSHA) - Company Net Income|Company Net Income uniqure.com (QURE)|Net Income MGTX|RGNX: Final Profit|Net Profit SLDB|Net Financial Result Ocugen Pharma|Company Net Income Pacific Biosciences PACB|BNTC: Company Profit|Design Therapeutics, Inc. - Net Profit|Rocket Pharma (RCKT) - Net Income|FDMT (4D Molecular Therapeutics Inc) - Net Income|LXEO - Net Financial Result|KRRO (Korro Bio Inc.) - Net Profit|Company Net Income EDIT|Company Net Income Silence Therapeutics plc (SLN)|Company Net Income PRQR (proqr.com)|Codexis - Net Income|Net Profit Sangamo BioSciences SGMO|Nautilus Biotechnology Inc - Net Profit|Company Net Income metagenomi.co|DTIL: Net Profit|Company Profit GBIO|Company Net Income Boundless Bio, Inc|Company Profit XCUR (Exicure Corp)|Net Profit IMNN|Net Profit phiopharma.com (PHIO)|Net Profit MBIO (Mustang Bio)|TransCode Therapeutics Inc. - Company Net Income|BNGO - Company Net Income|APDN: Company Net Income|IPA (immunoprecise.com) - Net Income|omegatherapeutics.com (OMGA) - Net Profit|OMIC (Singular Genomics) - Net Profit|Company Net Income Regulus Therapeutics, Inc. RGLS|Net Profit SYRS|Company Net Income TBIO (Telesis Bio, Inc)|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)